Cell-therapy company Vericel (VCEL) delivered strong third-quarter earnings driven by success from MACI, a cartilage cell implant that repairs joints, and Epicel, which …
BTIG’s Ryan Zimmerman shares his key takeaways from VCEL’s Analyst Day- with a confident verdict.
BTIG feels confident in Vericel core business as ixmyelocel-T’s future became uncertain.
